Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread?

Anaerobe

Volumn 40, Issue , 2016, Pages 35-40

  Polivkova, Sylvia ^a   Krutova, Marcela ^b   Petrlova, Katarina ^a   Benes, Jiri ^a   Nyc, Otakar ^b  

^a UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

ATLAS score; Clostridium difficile; MLVA; PCR Ribotype 176; Ribotyping; Thr82Ile

Indexed keywords

ARGININE; ASPARAGINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; FIDAXOMICIN; GLUTAMATE DEHYDROGENASE; GLUTAMIC ACID; HISTIDINE; ISOLEUCINE; LINCOSAMIDE; LYSINE; MACROLIDE; METRONIDAZOLE; MIKAMYCIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; THREONINE; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN;

AGED; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CLINICAL FEATURE; CLONAL SPECIES; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CZECH REPUBLIC; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERMB GENE; FECES ANALYSIS; FEMALE; GENETIC ANALYSIS; GYRA GENE; GYRB GENE; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; PREDICTION; PRIORITY JOURNAL; RECURRENT INFECTION; RIBOTYPING; RISK FACTOR; RPOB GENE; VARIABLE NUMBER OF TANDEM REPEAT; ADOLESCENT; ADULT; CLASSIFICATION; CROSS INFECTION; DIARRHEA; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; MUTATION; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; MUTATION; RETROSPECTIVE STUDIES; RIBOTYPING; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84966430231     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2016.05.002     Document Type: Article

References (38)

1. Freeman J., Bauer M.P., Baines S.D., Corver J., Fawley W.N., Goorhuis B., et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 2010, 23(3):529-549.
2. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., Wilcox M.H., Rupnik M., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377(9759):63-73.
3. Davies K.A., Longshaw C.M., Davis G.L., Bouza E., Barbut F., Barna Z., et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual,point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect. Dis. 2014, 14(12):1208-1219.
4. Freeman J., Vernon J., Morris K., Nicholson S., Todhunter S., Longshaw C., et al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin. Microbiol. Infect. 2015, 21(3):248. e9-248.e16.
5. Krutova M., Nyc O., Kuijper E.J., Geigerova L., Matejkova J., Bergerova T., et al. A case of imported Clostridium difficile PCR-ribotype 027 infection within the Czech Republic which has a high prevalence of C. difficile ribotype 176. Anaerobe 2014, 30:153-155.
6. Valiente E., Dawson L.F., Cairns M.D., Stabler R.A., Wren B.W. Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J. Med. Microbiol. 2012, 61(Pt 1):49-56.
7. Kuijper E.J., Coignard B., Tüll P., ESCMID Study Group for Clostridium difficile, EU Member States, European Centre for Disease Prevention and Control Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 2006, 12(6):2-18. Review.
8. Stubbs S.L., Brazier J.S., O'Neill G.L., Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J. Clin. Microbiol. 1999, 37(2):461-463.
9. Indra A., Huhulescu S., Schneeweis M., Hasenberger P., Kernbichler S., Fiedler A., et al. Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping. J. Med. Microbiol. 2008, 57(Pt 11):1377-1382.
10. Persson S., Torpdahl M., Olsen K.E. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin. Microbiol. Infect. 2008, 14(11):1057-1064. Erratum in: Clin Microbiol Infect. 2009; 15 (3); 296.
11. Dridi L., Tankovic J., Burghoffer B., Barbut F., Petit J.C. gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob. Agents Chemother. 2002, 46(11):3418-3421.
12. Curry S.R., Marsh J.W., Shutt K.A., Muto C.A., O'Leary M.M., Saul M.I., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin. Infect. Dis. 2009, 48(4):425-429.
13. Spigaglia P., Mastrantonio P. Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J. Med. Microbiol. 2004, 53(Pt 11):1129-1136.
14. van den Berg R.J., Schaap I., Templeton K.E., Klaassen C.H., Kuijper E.J. Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J. Clin. Microbiol. 2007, 45(3):1024-1028.
15. Marsh J.W., O'Leary M.M., Shutt K.A., Pasculle A.W., Johnson S., Gerding D.N., et al. Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J. Clin. Microbiol. 2006, 44(7):2558-2566.
16. Goorhuis A., Legaria M.C., van den Berg R.J., Harmanus C., Klaassen C.H., Brazier J.S., et al. Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative Clostridium difficile in a general hospital in Buenos Aires, Argentina. Clin. Microbiol. Infect. 2009, 15(12):1080-1086.
17. European Centre for Disease Prevention and Control European Surveillance of Clostridium difficile Infections. Surveillance Protocol Version 2.1 2015, ECDC, Stockholm.
18. Bauer M.P., Kuijper E.J., van Dissel J.T., European Society of Clinical Microbiology and Infectious Diseases European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 2009, 15(12):1067-1079.
19. Miller M.A., Louie T., Mullane K., Weiss K., Lentnek A., Golan Y., et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect. Dis. 2013, 13:148.
20. Debast S.B., Bauer M.P., Kuijper E.J., European Society of Clinical Microbiology and Infectious Diseases European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 2014, 20(2):1-26.
21. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 2010, 31(5):431-455.
22. Eastwood K., Else P., Charlett A., Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J. Clin. Microbiol. 2009, 47(10):3211-3217.
23. Nyč O., Pituch H., Matějková J., Obuch-Woszczatynski P., Kuijper E.J. Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland. Lancet 2011, 377(9775):1407.
24. Obuch-Woszczatyński P., Lachowicz D., Schneider A., Mól A., Pawłowska J., Ozdzeńska-Milke E., et al. Occurrence of Clostridium difficile PCR-ribotype 027 and it's closely related PCR-ribotype 176 in hospitals in Poland in 2008-2010. Anaerobe 2014, 28:13-17.
25. Lachowicz D., Pituch H., Obuch-Woszczatyński P. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe 2015, 31:37-41.
26. Krutova M., Matejkova J., Tkadlec J., Nyc O. Antibiotic profiling of Clostridium difficile ribotype 176-A multidrug resistant relative to C. difficile ribotype 027. Anaerobe 2015, S1075-9964(15):30045-30047. Aug 6.
27. Spigaglia P., Barbanti F., Mastrantonio P. European Study Group on Clostridium difficile (ESGCD). Multidrug resistance in European Clostridium difficile clinical isolates. J. Antimicrob. Chemother. 2011, 66(10):2227-2234.
28. Ackermann G., Tang Y.J., Kueper R., Heisig P., Rodloff A.C., Silva J., et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob. Agents Chemother. 2001, 45(8):2348-2353.
29. Dridi L., Tankovic J., Burghoffer B., Barbut F., Petit J.C. gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob. Agents Chemother. 2002, 46(11):3418-3421.
30. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J.S., Barbut F., Delmée M., et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J. Med. Microbiol. 2008, 57(6):784-789.
31. Drudy D., Kyne L., O'Mahony R., Fanning S. gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg. Infect. Dis. 2007, 13(3):504-505.
32. He M., Miyajima F., Roberts P., Ellison L., Pickard D.J., Martin M.J., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 2013, 45(1):109-113.
33. O'Connor J.R., Galang M.A., Sambol S.P., Hecht D.W., Vedantam G., Gerding D.N., et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 2008, 52(8):2813-2817.
34. Curry S.R., Marsh J.W., Shutt K.A., Muto C.A., O'Leary M.M., Saul M.I., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin. Infect. Dis. 2009, 48(4):425-429.
35. Kurti Z., Lovasz B.D., Mandel M.D., Csima Z., Golovics P.A., Csako B.D., et al. Burden of Clostridium difficile infection between 2010 and 2013: trends and outcomes from an academic center in Eastern Europe. World J. Gastroenterol. 2015, 21(21):6728-6735.
36. Balihar K., Kozak F., Kozeluhova J., Hejda V., Fremundova L., Krcma M., et al. Clostridium difficile infection in hospitalized patients at a Czech tertiary center: analysis of epidemiology, clinical features, and risk factors of fulminant course. Eur. J. Gastroenterol. Hepatol. 2014, 26(8):880-887.
37. Novak A., Spigaglia P., Barbanti F., Goic-Barisic I., Tonkic M. First clinical and microbiological characterization of Clostridium difficile infection in a Croatian University Hospital. Anaerobe 2014, 30:18-23.
38. Rao K., Micic D., Natarajan M., Winters S., Kiel M.J., Walk S.T., et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin. Infect. Dis. 2015, 61(2):233-241.